New Zealand markets open in 16 minutes
  • NZX 50

    12,185.65
    +57.44 (+0.47%)
     
  • NZD/USD

    0.6648
    -0.0043 (-0.64%)
     
  • ALL ORDS

    7,248.10
    -193.40 (-2.60%)
     
  • OIL

    86.69
    +1.09 (+1.27%)
     
  • GOLD

    1,818.00
    -34.50 (-1.86%)
     

Global IV and Oral Iron Drugs Market (2021 to 2026) - Featuring Vifor Pharma, Daiichi Sankyo & AMAG Pharmaceuticals Among Others - ResearchAndMarkets.com

·3-min read

The "IV and Oral Iron Drugs Market - Global Outlook and Forecast 2021-2026" report has been added to ResearchAndMarkets.com's offering.

In-depth Analysis and Data-driven Insights on the Impact of COVID-19 Included in this Global IV and Oral Iron Drugs Market Report

The global IV and oral iron drugs market by revenue is expected to grow at a CAGR of 11.6% during the period 2021-2026.

The global IV and oral iron drugs market is expected to grow due to the prevalence of iron deficiency (ID). This deficiency is a highly widespread nutritional disorder, affecting around one-fourth of the global population, especially women and children. It is one of the predominant causes of anemia. Anemia accounts for around 9% of the total global disease burden. Several chronic diseases are frequently associated with iron deficiency anemia (IDA) such as chronic kidney disease (CKD), chronic heart failure, cancer, and inflammatory bowel diseases. As anemia is associated with chronic fatigue, diminished well-being, and impaired cognitive function, the treatment with oral and IV iron drugs reduces the need for blood transfusion in patients. Further, the WHO rates ID as the most common and widespread nutritional disorder globally, and its prevalence is expected to grow with the aging population and the incidence of various chronic disorders.

The following factors are likely to contribute to the growth of the IV and Oral Iron Drugs market during the forecast period:

  • Strategic Collaborations & Licensing Opportunities

  • Investigational Iron Drugs

  • Increasing Availability of Branded Iron Therapeutics and Expanded Indication Approvals

The study considers the present scenario of the IV and Iron drugs market and its market dynamics for the period 2020-2026. It covers a detailed overview of several market growth enablers, restraints, and trends. The report offers both the demand and supply aspects of the market. It profiles and examines leading companies and other prominent ones operating in the market.

KEY QUESTIONS ANSWERED

1. What is the IV and oral iron drugs market size and growth rate during the forecast period?

2. What is the impact of COVID-19 on the intravenous iron drugs market share?

3. Which regions are expected to observe high revenues for IV and oral drugs during the forecast period?

4. Who are the notable market players in the global IV and oral iron drugs market?

5. What are the opportunities and threats faced by key vendors in the market?

Market Dynamics

Opportunities & Trends

  • Strategic Collaborations & Licensing Opportunities

  • Investigational Iron Drugs

  • Increasing Availability Of Branded Iron Therapeutics And Expanded Indication Approvals

Growth Enablers

  • Rising Incidence/Prevalence Of Iron Deficiency

  • High Demand For Dextran-Free Iv Iron Therapeutics

  • Growing Demand For Iron Replacement Therapies Among Kidney Disease Patients

Restraints

  • Presence of Alternative Options For Treating ID and IDA

  • Adverse Events Associated With Oral & IV Iron Drugs

  • Availability of Low-Cost Generic Iron Drugs

Companies Mentioned

  • Vifor Pharma

  • Daiichi Sankyo Company

  • AMAG Pharmaceuticals

  • Akebia Therapeutics

  • Shield Therapeutics

  • PHARMACOSMOS

  • Allergan

  • Sanofi

  • AOP Orphan Pharmaceuticals

  • AZAD Pharma

  • Ciron Drugs & Pharmaceuticals

  • Pfizer

  • Rockwell Medical

  • Salveo Lifecare

  • Sunny Pharmaceutical

For more information about this report visit https://www.researchandmarkets.com/r/5qaaoa

View source version on businesswire.com: https://www.businesswire.com/news/home/20210218005464/en/

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting